Predict your next investment

Corporation
HEALTHCARE | Biotechnology
lonza.com

See what CB Insights has to offer

Investments

8

Portfolio Exits

6

Partners & Customers

10

About Lonza Group

Lonza Group (SIX: LONN) (SGX: O6Z) is a chemicals and biotechnology company. The company provides product development services to the pharmaceutical and biologic industries, including organic, fine, and performance chemicals; custom manufacturing of biopharmaceuticals; chemical synthesis capabilities; and detection systems and services for the bioscience sector.

Lonza Group Headquarter Location

Muenchensteinerstrasse 38

Basel, CH-4002,

Switzerland

+41 61 316 81 11

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Lonza Group

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Lonza Group in 3 Expert Collections, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Lonza Group Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lonza Group Rank

Latest Lonza Group News

Global L-Carnitine Market Report 2021: Size, Share & Trends Analysis by Process (Bioprocess, Chemical Synthesis), Product (Food & Pharmaceutical Grade, Feed Grade) - ResearchAndMarkets.com

Oct 15, 2021

The global L-carnitine market size is expected to reach USD 276.0 million by 2028, expanding at a CAGR of 5.1%. Growing consumer awareness regarding product benefits, along with increasing demand from end-use industries such as pharmaceutical, nutraceutical, and animal feed, is projected to drive the market over the forecast period. L-carnitine and its derivatives are used for numerous applications including male infertility, kidney treatment, cardiovascular diseases, weight reduction, and bone mass. It is also used in various products including animal feed, health supplements, functional drinks, medicines, and other nutraceutical products. Manufacturers are focused on R&D activities to reduce the complexity in manufacturing techniques as well as product differentiation. Major manufacturers like Lonza, Ajinomoto, Sigma Tau Group, and Seikatsu have patented their manufacturing processes. Production of L-carnitine by chemical synthesis is executed on an industrial scale. However, manufacturers prefer bioprocess for the production, as the process generates higher yield and lesser waste as compared to chemical synthesis. Companies engaged in the production and export of L-carnitine follow stringent standards such as current goods manufacturing procedure (CGMP), sanitary standard operation procedure (SSOP), and ISO standards. Companies offering food-grade products are required to obtain kosher and halal certifications. In 2018, North America emerged as the largest regional market. The growth in this region can be attributed to increasing research and development activities in pharmaceutical and nutraceutical industries. Furthermore, increasing demand for pet supplements and animal feed formulations is expected to drive industry growth over the forecast period. L-carnitine Market Report Highlights Increasing preventive healthcare in major economies across the globe, including U.S., China, and India, has led to rising consumption of functional drinks, which in turn, is expected to propel product demand The market exhibits production of L-carnitine through biotechnological techniques using micro-organisms or enzymes. These processes use achiral precursors or racemic mixtures as raw materials for extraction of L-carnitine and offer the highest yield as compared to other means Increasing demand for animal feed from emerging economies such as China, India, and Vietnam are expected to drive the feed grade product segment over the forecast period Key L-Carnitine Market players include Lonza Group Ltd., Northeast Pharmaceutical Group Co., Ltd. (NEPG), Biosint S.p.A., Cayman Chemical, Merck KGaA, Tokyo Chemical Industry Co., Ltd., Ceva Sante Animale S.A., Kaiyuan Hengtai Chemical Co., Ltd., Chengda Pharmaceuticals Co. Ltd., Huanggang Huayang Pharmaceutical Co. Ltd., and Hubei Yuancheng Technology Co. Ltd. Manufacturers in the market enter into contracts with suppliers and buyers, thereby gaining a competitive edge in the market. They have also been investing heavily in R&D and capacity expansions to increase their market share. Market Dynamics

Lonza Group Investments

8 Investments

Lonza Group has made 8 investments. Their latest investment was in Affinia Therapeutics as part of their Series B on May 5, 2021.

CBI Logo

Lonza Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/3/2021

Series B

Affinia Therapeutics

$110M

No

3

4/15/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

3/27/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/13/2018

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

12/2/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/3/2021

4/15/2020

3/27/2020

1/13/2018

12/2/2016

Round

Series B

Series A

Series A

Corporate Minority

Series A

Company

Affinia Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$110M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

10

10

10

10

Lonza Group Portfolio Exits

6 Portfolio Exits

Lonza Group has 6 portfolio exits. Their latest portfolio exit was Lonza Group - Specialty Ingredients (Chemicals) on February 08, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/8/2021

Divestiture

$991

11

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

2/8/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Divestiture

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

11

10

10

10

10

Lonza Group Acquisitions

10 Acquisitions

Lonza Group acquired 10 companies. Their latest acquisition was Octane Biotech on October 31, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/31/2018

Corporate Majority

1

8/4/2017

Acq - Fin

Acquired

1

5/31/2017

Seed VC

$2.63M

Acquired

1

5/16/2017

Subscribe to see more

$99M

Subscribe to see more

10

12/15/2016

Acq - Fin

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

10/31/2018

8/4/2017

5/31/2017

5/16/2017

12/15/2016

Investment Stage

Acq - Fin

Seed VC

Acq - Fin

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

Total Funding

$2.63M

$99M

$99M

Note

Corporate Majority

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Lonza Group Partners & Customers

10 Partners and customers

Lonza Group has 10 strategic partners and customers. Lonza Group recently partnered with Pinteon Therapeutics on June 6, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

6/24/2021

Client

Pinteon Therapeutics

United States

Quote from Jennifer Cannon, Senior Vice President, Global Head of Mammalian Biologics, Lonza:. Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Antibody Targeting Alzheimer's Disease and Traumatic Brain Injury.

Newton , USA and Basel , Switzerland , 24 June 2021 -- Pinteon Therapeutics , a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of the tau protein , and Lonza announced today that the companies have expanded their manufacturing agreement to enable future clinical production of Pinteon Therapeutics 's lead candidate , PNT001 , which showed promising results in Phase 1 clinical study .

1

6/21/2021

Client

Valenza Biotech

United States

Lonza and ValenzaBio Enter Clinical Manufacturing Agreement

ValenzaBio , a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory indications , has entered a manufacturing agreement with Lonza .

3

6/3/2021

Licensee

Knowde

United States

Lonza Specialty Ingredients Renews Agreement With Knowde

SAN JOSE , CA - Knowde and Lonza Specialty Ingredients have renewed their agreement to continue marketing Lonza Specialty Ingredients 's products on Knowde .

1

4/14/2021

Client

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

4/8/2021

Client

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/24/2021

6/21/2021

6/3/2021

4/14/2021

4/8/2021

Type

Client

Client

Licensee

Client

Client

Business Partner

Pinteon Therapeutics

Valenza Biotech

Knowde

Country

United States

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

Quote from Jennifer Cannon, Senior Vice President, Global Head of Mammalian Biologics, Lonza:. Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Antibody Targeting Alzheimer's Disease and Traumatic Brain Injury.

Newton , USA and Basel , Switzerland , 24 June 2021 -- Pinteon Therapeutics , a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of the tau protein , and Lonza announced today that the companies have expanded their manufacturing agreement to enable future clinical production of Pinteon Therapeutics 's lead candidate , PNT001 , which showed promising results in Phase 1 clinical study .

Lonza and ValenzaBio Enter Clinical Manufacturing Agreement

ValenzaBio , a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory indications , has entered a manufacturing agreement with Lonza .

Lonza Specialty Ingredients Renews Agreement With Knowde

SAN JOSE , CA - Knowde and Lonza Specialty Ingredients have renewed their agreement to continue marketing Lonza Specialty Ingredients 's products on Knowde .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

3

1

10

10

Lonza Group Team

13 Team Members

Lonza Group has 13 team members, including former Chief Executive Officer, Roee Atlas.

Name

Work History

Title

Status

Roee Atlas

Chief Executive Officer

Former

Stefan Borgas

Chief Executive Officer

Former

Richard Ridinger

Chief Executive Officer

Former

Simon Sturge

Merck KGaA, Boehringer Ingelheim, OctoPlus, Vernalis, and RiboTargets

Chief Executive Officer

Former

Karen Fallen

President

Former

Name

Roee Atlas

Stefan Borgas

Richard Ridinger

Simon Sturge

Karen Fallen

Work History

Merck KGaA, Boehringer Ingelheim, OctoPlus, Vernalis, and RiboTargets

Title

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

President

Status

Former

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.